Trials / Conditions / Recurrent Primary Peritoneal Cavity Cancer

Recurrent Primary Peritoneal Cavity Cancer

17 registered clinical trials studyying Recurrent Primary Peritoneal Cavity Cancer.

Status	Trial	Sponsor	Phase
Completed	Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritone NCT02122185	University of Chicago	Phase 2
Withdrawn	Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or NCT01982487	Roswell Park Cancer Institute	Phase 1 / Phase 2
Completed	Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or R NCT02046421	University of Chicago	Phase 1
Terminated	Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal C NCT01962948	Fox Chase Cancer Center	Phase 1 / Phase 2
Completed	Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT01747798	Mayo Clinic	EARLY_Phase 1
Completed	Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Pri NCT01536054	Roswell Park Cancer Institute	Phase 1
Completed	Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer NCT01652794	Case Comprehensive Cancer Center	Phase 1
Completed	Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer NCT01764789	Ohio State University Comprehensive Cancer Center	N/A
Terminated	SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did No NCT01200797	National Cancer Institute (NCI)	Phase 2
Completed	Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recur NCT01673217	Roswell Park Cancer Institute	Phase 1
Completed	Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal NCT00388037	National Cancer Institute (NCI)	Phase 2
Completed	AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery NCT00348699	National Cancer Institute (NCI)	Phase 1
Completed	Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, NCT00278343	National Cancer Institute (NCI)	Phase 2
Completed	Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer NCT00096395	National Cancer Institute (NCI)	Phase 2
Completed	Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal NCT00083122	National Cancer Institute (NCI)	Phase 2
Completed	Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer NCT00026091	National Cancer Institute (NCI)	Phase 2
Withdrawn	Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tu NCT02050009	Fox Chase Cancer Center	Phase 1